Multicentric Castleman Disease
📧 Sign up to get email alerts when something new happens for Multicentric Castleman Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-12-05FDA Approved: SYLVANT — Supplemental Application (Recordati Rare Diseases, Inc.)
FDA approved a supplemental application for Sylvant (siltuximab) submitted by Recordati Rare Diseases, Inc.